Chemist Farah Benyettou is engineering something too small for the human eye to see. Her tiny “Trojan horses” are designed to travel through the body carrying medicine, with the potential to replace insulin injections with a pill and attack brain tumors from within.
Working with the Trabolsi Research Group at NYU Abu Dhabi, Benyettou develops nanoparticles and porous molecular structures, including covalent organic frameworks (COFs), designed to carry and protect medicines as they move through the body.
“For me, the aim is to design something simple that responds to its surroundings,” she says. “The material reacts to its environment and releases its therapeutic cargo under specific conditions.”
Now, after 14 years at NYUAD, she wants to see that research move closer to patients. Oral insulin could change daily life for people who depend on injections, while more precise cancer therapies could target tumors while limiting harm elsewhere in the body.
Building the science in Abu Dhabi
Trained in Paris, Benyettou studied at Université Paris 13, completing a PhD in chemistry with honors. Her doctoral work brought together chemistry, physics, and biology to develop magnetic nanoparticles capable of carrying anticancer drugs.
She continued exploring nanoparticles as drug carriers during her postdoctoral research before joining the Trabolsi Research Group at NYUAD in 2012.
“We started with relatively simple research,” she says. “As NYUAD developed, we gained access to more advanced instrumentation, broader expertise, and the ability to take the work much further.”
Today, Benyettou says the group has become a reference in the field, expanding the use of porous materials, including COFs, toward drug delivery, imaging, and other biomedical applications.
Replacing the needle
One of Benyettou’s major projects explores whether insulin could one day be delivered orally rather than by injection.
Insulin taken by mouth would normally be broken down in the stomach before it could reach the intestine. Benyettou and her collaborators have developed nanoparticles designed to protect it during gastrointestinal transit and facilitate its transport and controlled release in the intestine.
Nanoparticles are tiny structures that can act as carriers for medicines. By changing their design, Benyettou can control how they behave in different parts of the body. For oral insulin, one of the biggest challenges is protecting the medicine from the stomach's acidity so it can reach the intestine without breaking down.
In 2021, Benyettou and her collaborators demonstrated that their nanoparticles could successfully deliver insulin orally in diabetic rats, lowering their blood sugar levels. She is now finalizing follow-up research focused on helping the nanoparticles pass more effectively through the protective mucus lining of the intestine and improving their interaction with intestinal cells, with the aim of increasing insulin absorption into the bloodstream.
Early results from the follow-up research are promising. The newer system brought blood glucose close to the normal range within around two hours, with the effect sustained over 24 hours. The latest findings have not yet been published and will still need to undergo peer review, but Benyettou says the results so far are encouraging.
“The nanoparticle acts as protection, carrying the insulin safely through the stomach,” she says. “Once it reaches the intestine, the system is designed to facilitate insulin transport and release it in a controlled, glucose-responsive manner.”
Turning the tumor against itself
That same ability to control how a material behaves inside the body underpins another strand of Benyettou’s cancer research.
She and her collaborators have developed manganese-containing metal-organic molecules that can make tumors visible on an MRI scan while also helping to treat them. Once the molecules accumulate inside a tumor, its acidic environment causes them to break apart, triggering a localized therapeutic effect.
“The idea is that you can treat the tumor while also using imaging to follow how it responds and whether it is shrinking,” she says.
Studies in mice have included an aggressive brain tumor model. Benyettou says the molecules were able to cross the blood-brain barrier, accumulate in tumors, and help delineate them through imaging.
“The tumor’s own acidic environment triggers the system from within, releasing the active components where they are needed,” she explains.
From lab bench to patients
The next step is moving the technologies closer to patients. For the cancer work, further safety and preclinical studies would be needed before clinical trials could be considered.
The oral insulin technology has already been patented, and discussions are underway around investment and commercialization.
After more than a decade developing ways to deliver medicines more precisely, Benyettou is determined to push that work beyond the lab and towards treatments that could be used in clinical practice.
“That is ultimately what I want,” she says. “You spend years developing something in the lab, but the real goal is to see it reach patients and make a difference in their lives.”